Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. x x. 46/2008 Xx. m. x.

Xxxxxxxxxxxx zahraničních věcí xxxxxxx, xx dne 1. října 2017 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx a xxxxx dopingu xxx xxx 2018 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx¹⁾.

X xxxxx xxxxxx Xxxxxxx I xxxxxxxx xxxxxxx Parlament Xxxxx republiky x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Xxxxxxx I Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2018. Xxx Xxxxxx xxxxxxxxx xxxxxxxxx xxxx xxxxx Přílohy X x xxxxxxxx xxx 5. xxxxxx 2019.

Xxxx xxxxxx xxxxxx znění Xxxxxxx X x xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx I xxxxxx xx 1. xxxxx 2017 x xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Anglické xxxxx xxxxxx znění Xxxxxxx X a xxxx xxxxxxx xx xxxxxxx jazyka xx xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX XXXXXXXXXX LÁTEK X METOD XXXXXXX XXX ROK 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx xxxx spravován XXXX x bude xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X případě xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx verzí xxxx rozhodující anglická xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx od 1. xxxxx 2018 

XXXXXX ZAKÁZANÝCH XXXXX X METOD XXXXXXX XXX XXX 2018

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. xxxxx 2018

XXXXX X XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" kromě látek xx skupin X1, X2, X4.4, X4.5 x S6(a) a Xxxxxxxxxx xxxxx M1, X2 a M3.

ZAKÁZANÉ XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx látka, xxxxx xxxx xxxxxxxx v xxxxxxxxxxxxx sekcích Seznamu x xxxx xxxxxxxx xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. léčiva x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx použití), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX LÁTKY

Anabolické xxxxx xxxx zakázány.

1. ANABOLICKÉ XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion);

1-androsteron (3α-hydroxy-5α-androst-1-en-17-on);

bolandiol (xxxx-4-xx-3ß, 17ß-diol);

bolasteron;

danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);

dehydrochlormethyltestosteron (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17ß-ol);

drostanolon;

ethylestrenol (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-dihydroxyandrost-4-en-3-on);

kalusteron;

klostebol;

mestanolon;

mesterolon;

metandienon (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (methyltrienolon (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-hydroxy-5α-androst-1-en-3-on);

tetrahydrogestrinon (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.

b. Endogenní** XXX, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol);

androstendion (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion);

prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-hydroxyandrost-5-en-17-on);

testosteron;

a xxxxxx xxxxxxxxxx x xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Ostatní xxxxxxxxxx látky, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX, xxxx. xxxxxxx, LGD-4033, xxxxxxx x XXX140); xxxxxxx; xxxxxxx x xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

Xxx xxxxx xxxxxxx xxxx sekce: * "exogenní" xx xxxxxxxx k xxxxx, kterou xxxx xxxxxxxx přirozeně xxxxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. PEPTIDOVÉ XXXXXXX, RŮSTOVÉ XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx látky x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxxxx erytropoézu, xxxxxx, xxx xx x omezením xxxxx xx xx:

1.1 Agonisté xxxxxxxxxxxxxxxxx receptoru, xxxx

xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx založené na XXX (EPO-Fc, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); XXX-xxxxxxxxx xxxxxxxxxx a xxxxxx xxxxxxxxxx (např. XXXX 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (HIF), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (XX-4592); xxxxx.

1.3 Xxxxxxxxxx GATA, xxxx.

X-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), xxxx.

xxxxxxxxxxxx; sotatercept.

1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx. např.

asialo EPO; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx a xxxxxxxxx xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x xxxxxxxxxxxx hormon (XX) x jejich xxxxxxxxxx faktory, např. xxxxxxxxx, deslorelin, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x triptorelin, x xxxx.

2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin.

2.3 Xxxxxxx xxxxxx (XX), jeho xxxxxxxxx a xxxxxxxxxx xxxxxxx, xxxxxx, ale xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxx xxxxxxxxx xxxxxxx, např. XXX-9604 x xXX 176-191; xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x jeho xxxxxxx, xxxx. XXX-1295, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx hormonu (XXX), xxxx. xxxxxxx a xxxxxxxx ghrelinu, xxxx. xxxxxxxxxx, xxxxxxxxxx a xxxxxxxxxxx; uvolňující peptidy xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxx, XXXX-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, XXXX-5, XXXX-6 x hexarelin.

3. Xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxxx xxxxxxx, včetně, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxxxx xxxxxxx faktory (XXXx);

xxxxxxxxxxxx xxxxxxx xxxxxx (XXX);

xxxxxxxx xxxxxxx růstový xxxxxx-1 (IGF-1) a xxxx xxxxxxx

xxxxxxxxxx xxxxxxx xxxxxxx (XXX);

xxxxxxx faktor xxxxxxxx z krevních xxxxxxxx (XXXX);

xxxxxxxx- β4 x jeho xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX).

Xxxxx xxxxxxx xxxxxxx a modulátory xxxxxxxxx xxxxxxx ovlivňující xxxxxxx nebo degradaci xxxxxxxx xxxxx, xxxxx x xxxxxx, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx typy svalových xxxxxx.

X3. BETA2- XXXXXXXX

Xxxxxxx xxxxxxxxxx i neselektivní xxxx-2 xxxxxxxx, xxxxxx xxxxx optických isomerů, xxxx zakázáni.

Zahrnují (ale xx s xxxxxxxx xxxxx na xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prokaterol; xxxxxxxxxx; xxxxxxxxxx; salmeterol; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx jsou:

• inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx v xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx každých 12 hodin xx xxxxxxxxx xxxxx;
• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx vyšší xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx než 40 xx/xx xxxxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxxx použití, ale xxxx považována xx xxxxxxxxx xxxxxxxxxxx nález, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx výsledek xxx způsoben xxxxxxxxxxxxx xxxxxx (v inhalaci) xxxxx, než xxxx xxxxxxx maximální xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx jsou následující xxxxxxxxx x metabolické xxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, ale ne x xxxxxxxx xxxxx xx ně.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

tamoxifen;

toremifen, xxx ne x xxxxxxxx xxxxx na xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (AMPK), xxxx. XXXXX; x Xxxxxxxx Xxxxxxxxx xxxxx aktivovaného xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516);

5.2 xxxxxxxx x xxxxxxxx xxxxxxxx;

5.3 meldonium;

5.4 xxxxxxxxxxxx.

X5. XXXXXXXXX X MASKOVACÍ XXXXX

Xxxxxxxxxxx diuretika x xxxxxxxxx xxxxx xxxx xxxxxxxx, xxxxxx xxxx xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (např. xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx); xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

• Xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx); xxxxxxxxxx x xxxxxxx (xxxx. xxxxxxxxx), ale xx x xxxxxxxx xxxxx na ně.

S xxxxxxxx:

• xxxxxxxxxxxx; pamabromu x xxxxxx podání inhibitorů xxxxxxxxxxxxxx (xxxx. dorzolamidu x brinzolamidu)

• Lokálního xxxxxx xxxxxxxxxxxx pro xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx stanoveným xxxxxxxx xxxxxxx (tj. xxxxxxxxxx, salbutamol, katin, xxxxxxx, metylefedrin a xxxxxxxxxxxxx) xx Vzorku Xxxxxxxxx kdykoliv nebo xxxxxxxx Při Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Pozitivní xxxxxxxxxxx nález, xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx výjimku (TV) xx xxxx látku xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx diuretikum xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxx nebo xxxxxxxxxxxxx jakéhokoliv množství xxxxxxxxx, alogenní (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx krvinek x jim xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx dodávky xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx hemoglobinové xxxxxxxx (xxxx. krevní xxxxxxxx xxxxxxxx xx xxxxxxxxxxx x xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx ne x xxxxxxxx xxxxx xx xx. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx zakázána xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Pokus x Podvod, xx xxxxxx xxxxxxx integritu x xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx a/nebo xxxxxx (xxxx. proteázami) xxxx, xxx xx x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx infuze x/xxxx injekce více xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx přijatých x xxxxxxx xxxxxxxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X důvodu xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Použití xxxxxxxx nukleových xxxxxxx xxxx jejich analogů;

2. Xxxxxxx xxxxxxxxx produkovaných xxxxxxxxx, xxxxxxxxxxx k xxxxxxxxxxx xxxxxxxx xxxxxx x/xxxx x transkripční xxxx xxxxxxxxxxxx xxxxxxxx xxxxxx xxxxxxx.

3. Xxxxxxx xxxxxxxxxx nebo geneticky xxxxxxxxxxxxxx xxxxx;

XXXXX X XXXXXX XXXXXXXX PŘI XXXXXXX

Xxxxx xxxxxxxxx S0 xx X5 x X1 xx X3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx zakázané x xxxxxxxxxxx skupiny:

ZAKÁZANÉ LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx včetně xxxxx jejich xxxxxxxxxx xxxxxxxxx xxxxxxx, např. x- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx uvedeno x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx stimulancia.

Zahrnují (ale xx s omezením xxxxx xx xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxx;

xxxxx**;

xxxxxxx a xxxx analoga (xxxx. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (metylhexanamin);

niketamid;

norfenefrin;

oktopamin;

oxilofrin (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x případě xxxxxx xxxxxxxx/xxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx rok 2018*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Xxxx xxxxx xxxx xxxxxxxx xx Monitorovacího programu 2018 x nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.

*** Xxxxxxx a methylefedrin: xxxx xxxxxxxx xxx xxxxxxxxxxx vyšší xxx 10 mikrogramů v 1 ml moči.

**** Xxxxxxxxx (xxxxxxxxx): není xxxxxxx xxx xxxxxxxx xxxxxx, xxxx. xxxxx, xxxx xxxxxxxx xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx koncentrace x xxxx je xxxxx xxx 150 xxxxxxxxxx na mililitr.

S7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. KANABINOIDY

Následující xxxxxxxxxxx xxxx xxxxxxxx:

• Xxxxxxxx xxxxxxxxxxx, xxxx. hašiš, konopí x xxxxxxxxx.

• Xxxxxxxxxx xxxxxxxxxxx, xxxx. delta9-tetrahydrokanabinol (XXX) x xxxxxxx xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.

Xxxxxx, xxx xx x xxxxxxxx pouze na xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX XXXXXXXX X&xxxx;XXXXXXXX XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx jsou xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x xxx xx xx označeno x Mimo xxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (FIS) - xxxxx xx lyžích x xxxxxxxxxxx lyžování-skoky x X-xxxxx, a xxxxxxxxx U-rampa x "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx xxxxxxxx) (CMAS) x disciplínách xxxxxxxxxx xxxx s ploutvemi xxxx bez xxxxxxx, xxxxxxxxx xxxxx x xxxxxxxxx xxxx xxx xxxxxxx, free xxxxxxxxx, xxxx xxxx, spearfishing, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx xx terč x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, IPC)*

• Šipky (WDF)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx x xxxxxxxx pouze xx xx.

Xxxxxxxxx

Xxxxxx xxxxxxx č. 36/2019 Xx. x. x. xxxxx xxxxxxxxx xxxx 26.7.2019.

Xxxxxx předpis x. 36/2019 Sb. x. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 32/2023 Sb. m. s. x účinností xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx jiných xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx, přijatá xxx 19. xxxxx 2005 x Paříži, xxxx xxxxxxxxx x xxxxxxxxx xxxxx a x xxxxxxxxx do xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx překladu Xxxxxx xx českého xxxxxx xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.